Radius Health (RDUS) Delay in U.S. 'Bad News', Maxim Group Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil rises as renewed US-Iran strikes stoke supply fears
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
Radius Health Has Submitted a Marketing Authorization Application for the Investigational Drug Abaloparatide-SC for the Treatment of Postmenopausal Osteoporosis in Europe
November 17, 2015 8:32 AM ESTTodays submission represents the Companys first application to register a new medicineIf approved, abaloparatide-SC would be the first new bone anabolic in Europe since 2003Company provides update on timing for NDA submission
WALTHAM, Mass., Nov. 17, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS), today announced that it has submitted a Marketing Authorization Application (MAA) for an investigational, once-daily subcutaneous injection of abaloparatide, a novel synthetic peptide. In addition to other data, the MAA is supported by clinical studies exploring the use of abaloparatide for the... More
